Oncopeptides AB (LTS:0RN4) Common Stock: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RN4 Oncopeptides AB LTS:0RN4
45 GF Score
Price kr1.61
GF Value kr4.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Common Stock?

Oncopeptides AB LTS:0RN4 45 Common Stock is kr0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0RN4 with a GF Score™ of 45/100 and a GF Value™ of kr4.41 (Possible Value Trap). The stock has 3 warning signs investors should review.

Oncopeptides AB's quarterly common stock increased from Sep. 2025 (kr0.00 Mil) to Dec. 2025 (kr30.30 Mil) but then declined from Dec. 2025 (kr30.30 Mil) to Mar. 2026 (kr0.00 Mil).

Oncopeptides AB's annual common stock increased from Dec. 2023 (kr10.51 Mil) to Dec. 2024 (kr23.91 Mil) and increased from Dec. 2024 (kr23.91 Mil) to Dec. 2025 (kr30.30 Mil).

Oncopeptides AB Common Stock Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB Common Stock Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.37 10.48 10.51 23.91 30.30

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 30.30 0.00
LTS:0RN4
45GF Score
Oncopeptides AB LTS:0RN4
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of kr0.00 Mil mean?
Oncopeptides AB (LTS:0RN4) has a Common Stock of kr0.00 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Common Stock too high?
Oncopeptides AB's current Common Stock is kr0.00 Mil. Overall, Oncopeptides AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Common Stock compare to VRTX and REGN?
Oncopeptides AB's Common Stock of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Common Stock is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (LTS:0RN4) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.41, compared to a current price of kr1.61 — trading 63.5% below its estimated fair value. The current Common Stock is kr0.00 Mil. Oncopeptides AB's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Oncopeptides AB (LTS:0RN4), the current Common Stock is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.61 is trading 63.5% below its estimated GF Value™ of kr4.41. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for LTS:0RN4:

  • Common Stock: kr0.00 Mil
  • GF Value™: kr4.41 vs. price of kr1.61 (63.5% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
45GF Score

Get the complete analysis for LTS:0RN4

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.61
Price
kr4.41
GF Value